The Syngap research roadmap stages

Why create a roadmap ?

- It's best practice to obtain a disease cure in the rare disease community
- Highlights future dependencies to ensure project timelines are aligned, eliminating potential bottlenecks
- Connect the community on projects
- Provides clear priorities for the community on paths to a cure and treatment
- Ensure our resources are aligned, focused, co-ordinated and not duplicated
- Establish Syngap community assets, making Syngap attractive for biotechs e.g. establish tools like a Natural history study, models

* Clinical trials phases based on the Dravet foundation clinical trial pipeline https://www.dravetfoundation.org/dsffunded-research/pipeline/

		Syngap Glob
Clinical Trials*	5.1 Phase 15.2 Phase 25.3 Phase 35.4 FDA Approval5.5 Phase 45.6 Commercial	Roadmap stage
Pre-clinical Research Cure	4.1 Gene Therapy (ASO)4.2 Drug Sci4.3 Small Molecules4.4 AAV4.5 CRISPR	reen
Pre-clinical Research Treat	3.1 Brain- Gut 3.2 Symptomatic Treatment	
Research Knowledge	2.1 Basic Science2.2 Geno-pheno Analysis2.3 Tools & Protocols	
Research Assets	1.1 Outcome Measures 1.3 Models 1.5 Research bank	1.2 Biomarkers 1.4 Human Cells 1.6 Biobank

The Syngap research roadmap

Roadmap stage	Proiect		Lead Nation		Timeline			
				2020	H1 2021	H2 2021	2022+	
Outcome measures	Natural History Study (Scheffer)	Australia		•				
Biomarkers	Biomarkers – gait analysis (Necker Hospital)	France						
Models	Mouse models (Huganir, Grant, Komiyama). Multiple mutations (Brose, Holder, Rumbaugh)	Multiple						
Human Cells	Patient Cell Lines (Rumbaugh, Huganir, Clement, Petrou, Holder, Coba, Brüstle, Treutlein)	Multiple		•				
Basic Science	Animal based Syngap research C2 domain (Kind)	Austria						
Basic Science	Molecular Syngap project (Sarah Shoichet)	Germany						
Basic Science	Syngap protein synthesis – excitatory synapse (Clement)	India						
Basic Science	Epigenetics project (Heller)	Multiple						
Basic Science	SYNGAP isoform dynamics (Araki, Huganir)	US						
Geno-phenol analysis	Effects on function of neurons comprising key striatal and dopaminergic circuits (Bateup)	US						
Geno-phenol analysis	Geno-pheno analysis into hyperlocomotor activity, impaired memory, pain stimuli. (Nakajima, Miyakawa, Grant, Komiyama)	Japan						
Geno-phenol analysis	EEG pathogenesis research (Kadam)	US						
Symptomatic treatment	Microbiome study (Hsiao)	Australia		•				
Symptomatic treatment	Drug Screen (Rumbaugh, Clement), hiPSC (Bayes, Schülke)	Multiple						
Symptomatic treatment	Statins (Kluger, Clement)	Multiple						
Gene Therapy	3 projects; ASO (Petrou, Stoke), Natural ASO (Huganir)	Multiple		•			A ton	
Small molecules	Syngap regulator targets for small molecules, high throughput screen (Courtney)	Austria		•				
Small molecules	Testing pharmacological agents that target intracellular pathways (Ras, ERK, MTOR) to correct synaptic abnormalities (Michaud)	Canada				S	Ingap Globa	